A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
- DOI
- 10.1186/s40164-022-00270-5
- Published
- 2022 Mar 22
- Container
- Experimental hematology & oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s40164-022-00270-5,
title = {A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.},
author = {Zhang Y and Li S and Wang Y and Lu Y and Xu Y and Rao Q and Wang H and Xing H and Tian Z and Tang K and Lv L and Wang M and Wang J},
year = {2022},
journal = {Experimental hematology \& oncology},
doi = {10.1186/s40164-022-00270-5},
url = {https://doi.org/10.1186/s40164-022-00270-5}
}RIS
TY - JOUR TI - A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. AU - Zhang Y AU - Li S AU - Wang Y AU - Lu Y AU - Xu Y AU - Rao Q AU - Wang H AU - Xing H AU - Tian Z AU - Tang K AU - Lv L AU - Wang M AU - Wang J PY - 2022 JO - Experimental hematology & oncology DO - 10.1186/s40164-022-00270-5 UR - https://doi.org/10.1186/s40164-022-00270-5 ER -
APA
Y, Z., S, L., Y, W., Y, L., Y, X., Q, R., H, W., H, X., Z, T., K, T., L, L., M, W., & J, W. (2022). A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.. Experimental hematology & oncology. https://doi.org/10.1186/s40164-022-00270-5
Source records
- pubmed · retrieved 2026-09-26T12:59:49.490Z